Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT).
Sakata Y, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Kobe H, Matsumoto H, Yokoi T, Sato Y, Uenami T, Saito G, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Among authors: hara s. Eur J Cancer. 2021 Dec;159:144-153. doi: 10.1016/j.ejca.2021.09.041. Epub 2021 Nov 5. Eur J Cancer. 2021. PMID: 34749119
Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study.
Kataoka Y, Hirano K, Narabayashi T, Hara S, Fujimoto D, Tanaka T, Ebi N, Tomii K, Yoshioka H. Kataoka Y, et al. Among authors: hara s. Cancer Chemother Pharmacol. 2018 Feb;81(2):333-337. doi: 10.1007/s00280-017-3498-z. Epub 2017 Dec 11. Cancer Chemother Pharmacol. 2018. PMID: 29230503
Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study.
Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Kim YH, Tomii K, Ishida T, Hirabayashi M, Hara S, Ishitoko M, Fukuda Y, Hwang MH, Sakai N, Fukui M, Nakaji H, Morita M, Mio T, Yasuda T, Sugita T, Hirai T. Fujimoto D, et al. Among authors: hara s. Lung Cancer. 2018 May;119:14-20. doi: 10.1016/j.lungcan.2018.02.017. Epub 2018 Mar 2. Lung Cancer. 2018. PMID: 29656747
Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy.
Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Hata T, Kim YH, Tomii K, Ishida T, Hirabayashi M, Hara S, Ishitoko M, Fukuda Y, Hwang MH, Sakai N, Fukui M, Nakaji H, Morita M, Mio T, Yasuda T, Sugita T, Hirai T. Fujimoto D, et al. Among authors: hara s. J Thorac Oncol. 2019 Mar;14(3):468-474. doi: 10.1016/j.jtho.2018.10.167. Epub 2018 Nov 20. J Thorac Oncol. 2019. PMID: 30468872 Free article.
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).
Tamiya M, Tamiya A, Hosoya K, Taniguchi Y, Yokoyama T, Fukuda Y, Hirano K, Matsumoto H, Kominami R, Suzuki H, Hirashima T, Uchida J, Morita M, Kanazu M, Sawa N, Kinoshita Y, Hara S, Kumagai T, Fujimoto D. Tamiya M, et al. Among authors: hara s. Invest New Drugs. 2019 Dec;37(6):1266-1273. doi: 10.1007/s10637-019-00843-y. Epub 2019 Aug 7. Invest New Drugs. 2019. PMID: 31392549
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
Kawachi H, Tamiya M, Tamiya A, Ishii S, Hirano K, Matsumoto H, Fukuda Y, Yokoyama T, Kominami R, Fujimoto D, Hosoya K, Suzuki H, Hirashima T, Kanazu M, Sawa N, Uchida J, Morita M, Makio T, Hara S, Kumagai T. Kawachi H, et al. Among authors: hara s. Invest New Drugs. 2020 Feb;38(1):211-218. doi: 10.1007/s10637-019-00882-5. Epub 2019 Nov 30. Invest New Drugs. 2020. PMID: 31784866
Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Hosoya K, Fujimoto D, Morimoto T, Kumagai T, Tamiya A, Taniguchi Y, Yokoyama T, Ishida T, Hirano K, Matsumoto H, Kominami R, Tomii K, Suzuki H, Hirashima T, Uchida J, Morita M, Kanazu M, Sawa N, Makio T, Hara S, Tamiya M. Hosoya K, et al. Among authors: hara s. Clin Lung Cancer. 2020 Jul;21(4):e315-e328. doi: 10.1016/j.cllc.2020.01.003. Epub 2020 Feb 4. Clin Lung Cancer. 2020. PMID: 32113737
2,170 results